The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

Terremoto Biosciences Inc. has synthesized new 3H-imidazo[4,5-b]pyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB-α) inhibitors reported to be useful for the treatment of ...

Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival Eligible patients had AKT1 E17K–mutated metastatic tumors that progressed with standard ...